Loading patent…
AssigneesInstitut National de la Sante et de la Recherche Medicale, Assistance Publique-Hopitaux de Paris, Université Paris Cité, Universite Paris Est Creteil Val De Marne
InventorsArmand BENSUSSAN, Jérôme GIUSTINIANI, Martine BAGOT, Adèle DE MASSON D'AUTUME, Nicolas ORTONNE, Maxime BATTISTELLA, Anne MARIE-CARDINE
Estimating the term…
T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sezary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sezary cells and showed the expression of CCR8 (CD198) by Sezary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas.
A method of treating a T-cell lymphoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent capable of inducing cell death of CCR8 expressing cancer cells.
A method of diagnosing a T-cell lymphoma in a patient comprising detecting the expression level of CCR8 in a sample obtained from the patient.
Dependencies are inferred from the claim text.